Clinical Trial Update: Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating denosumab for preventing skeletal disease progression in children with fibrous dysplasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrous Dysplasia

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) | Conditions: Fibrous Dysplasia | Phase 2 | Status: COMPLETED